AMN Healthcare Services Inc (AMN)

41.80
NYSE : Health Care
Prev Close 41.80
Day Low/High 0.00 / 0.00
52 Wk Low/High 26.00 / 44.99
Avg Volume 592.50K
Exchange NYSE
Shares Outstanding 47.72M
Market Cap 1.99B
EPS 2.20
P/E Ratio 19.44
Div & Yield N.A. (N.A)

Latest News

Trifecta Stocks Weekly Roundup

We said good-bye to one position and trimmed 2 others as all major indices closed higher once again.

Growth Seeker Weekly Summary

We trimmed 2 portfolio positions and raised price targets on 2 other names last week.

AMN Chart Shows a Breakout

Last Friday this name broke from December resistance with some bold action.

Trifecta Stocks Weekly Roundup

We added one new position to the portfolio and bolstered the Bullpen as the market continued its grind higher.

We're Boosting Our Price Target on AMN Healthcare

We are upping our target by $4 after yesterday's earnings report and conference call.

Raising Our Price Target on AMN Healthcare

We're hiking our target by $4 following yesterday's earnings report and conference call.

AMN Healthcare's Quarterly Results in Good Shape

Health-care workforce company's 4Q revenue and earnings beat consensus expectations.

AMN Healthcare Has Successful Quarterly Checkup

Health-care workforce company reports better-than-expected 4Q results on both the top and bottom lines.

Growth Seeker Weekly Summary

Several portfolio holdings continued to climb higher with the broader market last week.

Trifecta Stocks Weekly Roundup

Once again, a number of our One-rated positions outperformed a rising overall market this week.

Growth Seeker Weekly Summary

We exited one portfolio position last week amid a largely flat market.

Peak Health Solutions Named Category Leader In 2017 Best In KLAS Report

Peak Health Solutions Named Category Leader In 2017 Best In KLAS Report

KLAS recognizes Peak Health Solutions as the Category Leader in Outsourced Coding

Trifecta Stocks Weekly Roundup

It was a busy week of earnings for the portfolio as the market ended up largely unchanged.

Growth Seeker Weekly Summary

A majority of Growth Seeker's positions outperformed the market last week, but we continue to keep an eye on valuation.

Growth Seeker Portfolio: Earnings Start to Give Clearer Picture

Growth Seeker Portfolio: Earnings Start to Give Clearer Picture

The portfolio had several outperformers during the first week of the new president's term.

Trifecta Stocks Weekly Roundup

The portfolio had several outperformers during the first week of the new president's term and somewhat mixed earnings.

AMN Looks Good in the Long Term, Despite Recent Volatility

A review of this portfolio position in light of price action and Trump policy maneuvers.

AMN and Dycom Both Look Good Long Term

A review of these 2 portfolio names in light of Trump policy maneuvers and upcoming earnings reports.

Growth Seeker Weekly Summary

'Growth' stocks took a back seat to dividend payers last week as earnings and President Trump took center stage.

Trifecta Stocks Weekly Roundup

We expect more value to develop in the markets as we enter the heart of earnings season and put the inauguration in the rear view mirror.

Growth Seeker Weekly Summary

We initiated a new portfolio position as earnings season and EU issues heated up.

Trifecta Stocks: Now It Gets Really Interesting

Trifecta Stocks: Now It Gets Really Interesting

Earnings season heats up next week as Donald Trump is sworn in as president.

Trifecta Stocks Weekly Roundup

We initiated one new position and trimmed/added to several others as December-quarter earnings season kicked off.

Dire Health Care Forecast Is Good for AMN

With the population aging and nurses in high demand, this new portfolio stock will benefit.

Initiating a Position in Health Care

AMN Healthcare has benefited from the nursing shortage.

AMN Healthcare Poised for Move Higher

The name became overbought in December and pulled back a bit, but buyers appear to be coming back to the party.

Growth Seeker Weekly Summary

The year started off decidedly positive for the markets and many portfolio positions, but we believe a challenging tightrope lies ahead.